Leadiant Biosciences, Inc.
Rockville, MD U.s. Division
- UEI
- XEEKF6DJLC34
- CAGE
- 0TH45
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 530 Gaither Rd #300, Rockville, MD 20850, USA
- Website
- leadiant.com
- Founded
- 1980
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $22,000 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Cipla USA Inc. | Warren, NJ | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| ADC Therapeutics America, Inc. | New Providence, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Incyte Corporation | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Leadiant Biosciences, Inc. U.S. Division is a foreign-owned, for-profit pharmaceutical manufacturer registered to receive federal contract awards since December 2001. The company specializes in developing and distributing drug therapies, with a focus on rare diseases and specialized pharmaceutical products. Leadiant Biosciences provides a range of goods to the federal government, primarily in the form of pharmaceutical compounds and medications. Their federal contracting activities predominantly involve supplying both research-grade compounds and approved drug therapies to agencies within the healthcare sector, particularly the Department of Veterans Affairs (VA) and the National Institutes of Health (NIH).
Recent federal contract awards to Leadiant Biosciences showcase the company's diverse capabilities in pharmaceutical supply. In May 2024, the company was awarded a $22,000 firm fixed-price purchase order by the NIH's National Human Genome Research Institute for the delivery of N-acetyl-D-mannosamine monohydrate (MANNAC), a specialized research compound. This award demonstrates Leadiant's ability to provide high-quality materials for advanced medical research. Additionally, Leadiant has supplied the VA with Matulane, a chemotherapy drug, through multiple delivery orders in 2020. These orders, each valued at $5,442.92, were issued to Veterans Integrated Service Networks 9 and 23, indicating the company's role in supporting cancer treatment across VA medical facilities. Notably, none of these contract awards carried set-aside designations, suggesting that Leadiant competes in full and open competition for federal business.
Leadiant Biosciences holds two significant federal contract Indefinite Delivery Vehicles (IDVs) that further solidify its relationship with the VA. The first is a Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, awarded in September 2021 with a ceiling value of $4,457,440 and running through August 2026. This multiple-award vehicle allows VA facilities to order a variety of medications from Leadiant. The second IDV is a single-award Blanket Purchase Agreement (BPA) specifically for the supply of Matulane, with a $465,000 ceiling value and performance period through October 2025. This BPA, which falls under the parent FSS contract, streamlines the procurement process for VA medical centers requiring Matulane. Both IDVs were awarded by the VA's National Acquisition Center, highlighting Leadiant's strategic positioning as a key pharmaceutical supplier to the VA healthcare system. The combination of these vehicles demonstrates Leadiant's capacity to provide both a broad range of pharmaceutical products and specialized cancer treatments to federal healthcare providers.
Quick answers
Is Leadiant Biosciences, Inc. registered in SAM.gov?
Yes. Leadiant Biosciences, Inc.'s SAM.gov registration is active through September 11, 2027.
Which contract vehicles does Leadiant Biosciences, Inc. hold?
Leadiant Biosciences, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Leadiant Biosciences, Inc. received in federal contracts?
Federal contracts obligated $22,000 to Leadiant Biosciences, Inc. in fiscal years 2023 through 2027.
What is Leadiant Biosciences, Inc.'s most recent federal award?
Leadiant Biosciences, Inc.'s most recent federal contract award is 3 kits of 600 sachets, each containing 4G of mannac per sachet. (n-acetyl-d-mannosamine monohydrate) (75N92E24P00143), from National Human Genome Research Institute (NIH), on May 6, 2024.
On GovTribe
See Leadiant Biosciences, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors